Cargando…

Systemic Chemokine Levels with “Gut-Specific” Vedolizumab in Patients with Inflammatory Bowel Disease—A Pilot Study

Vedolizumab, a gut-specific biological treatment for inflammatory bowel disease (IBD), is an antibody that binds to the α(4)β(7) integrin and blocks T-cell migration into intestinal mucosa. We aimed to investigate chemokine levels in serum of IBD-patients treated with vedolizumab. In this pilot stud...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zwicker, Stephanie, Lira-Junior, Ronaldo, Höög, Charlotte, Almer, Sven, Boström, Elisabeth A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5578211/ https://www.ncbi.nlm.nih.gov/pubmed/28829369 http://dx.doi.org/10.3390/ijms18081827

Ejemplares similares

Salivary and Serum Inflammatory Profiles Reflect Different Aspects of Inflammatory Bowel Disease Activity
por: Majster, Mirjam, et al.
Publicado: (2020)

Differences in Whole-Blood Transcriptional Profiles in Inflammatory Bowel Disease Patients Responding to Vedolizumab Compared with Non-Responders †
por: Haglund, Sofie, et al.
Publicado: (2023)

Interleukin 34: a new modulator of human and experimental inflammatory bowel disease
por: Zwicker, Stephanie, et al.
Publicado: (2015)

Receptor-Type Protein-Tyrosine Phosphatase ζ and Colony Stimulating Factor-1 Receptor in the Intestine: Cellular Expression and Cytokine- and Chemokine Responses by Interleukin-34 and Colony Stimulating Factor-1
por: Zwicker, Stephanie, et al.
Publicado: (2016)

Periodontitis is associated to increased systemic inflammation in postmyocardial infarction patients
por: Lira-Junior, Ronaldo, et al.
Publicado: (2021)

Long-term outcomes of vedolizumab in inflammatory bowel disease: the Swedish prospective multicentre SVEAH extension study
por: Visuri, Isabella, et al.
Publicado: (2023)

Predicting Response to Vedolizumab in Inflammatory Bowel Disease
por: Meserve, Joseph, et al.
Publicado: (2020)

Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH study
por: Eriksson, Carl, et al.
Publicado: (2021)

Vedolizumab, a gut-specific monoclonal antibody, renews hope for an alternative to anti-TNF therapy in inflammatory bowel diseases
por: Rezaie, Ali
Publicado: (2014)

Long‐term safety of vedolizumab for inflammatory bowel disease
por: Loftus, Edward V., et al.
Publicado: (2020)

Vedolizumab in the treatment of inflammatory bowel disease: evolving paradigms
por: Crooks, Benjamin, et al.
Publicado: (2020)

Effect of obesity on vedolizumab response in inflammatory bowel disease
por: Levine, Louis J., et al.
Publicado: (2022)

Is Vedolizumab Truly Gut Selective? It May Not Affect the Immunogenicity of Vaccines in Patients With Inflammatory Bowel Disease
por: Lee, Alexander S, et al.
Publicado: (2020)

Designing biologic selectivity for inflammatory bowel disease – role of vedolizumab
por: Krupka, Niklas, et al.
Publicado: (2014)

Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease
por: Fleisher, Mark, et al.
Publicado: (2018)

A review of vedolizumab and ustekinumab for the treatment of inflammatory bowel diseases
por: Shim, Hang Hock, et al.
Publicado: (2018)

Vedolizumab Is Safe in Elderly Veteran Patients With Inflammatory Bowel Disease
por: Leung, Kenneth, et al.
Publicado: (2021)

Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases
por: Lynch, Kate D., et al.
Publicado: (2020)

Periodontal and inflammatory bowel diseases: Is there evidence of complex pathogenic interactions?
por: Lira-Junior, Ronaldo, et al.
Publicado: (2016)

Effect of Vedolizumab on Anemia of Chronic Disease in Patients with Inflammatory Bowel Diseases
por: Scarozza, Patrizio, et al.
Publicado: (2020)

Use of Vedolizumab in Inflammatory Bowel Disease: A Single-Center Experience
por: Erdoğan, Çağdaş, et al.
Publicado: (2022)

The Role of Vitamin D in Patients with Inflammatory Bowel Disease Treated with Vedolizumab
por: Abraham, Bincy P., et al.
Publicado: (2023)

Inflammatory markers in saliva and urine reflect disease activity in patients with systemic lupus erythematosus
por: Ruacho, Guillermo, et al.
Publicado: (2022)

Real-World Study on Vedolizumab Serum Concentration, Efficacy, and Safety after the Transition from Intravenous to Subcutaneous Vedolizumab in Inflammatory Bowel Disease Patients: Single-Center Experience
por: Oršić Frič, Vlasta, et al.
Publicado: (2023)

Genetic variation and expression levels of tight junction genes identifies association between MAGI3 and inflammatory bowel disease
por: Norén, Elisabeth, et al.
Publicado: (2017)

Association Between Vedolizumab Levels, Anti-vedolizumab Antibodies, and Endoscopic Healing Index in a Large Population of Patients with Inflammatory Bowel Diseases
por: Yarur, Andres J., et al.
Publicado: (2020)

Vedolizumab does not increase risk of clostridium difficile infection in patients with inflammatory bowel disease using vedolizumab: A retrospective cohort study
por: Saad Alshahrani, Abdulaziz, et al.
Publicado: (2023)

Vedolizumab: A novel anti-integrin drug for treatment of inflammatory bowel disease
por: Singh, Harmanjit, et al.
Publicado: (2016)

Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases
por: Bertani, Lorenzo, et al.
Publicado: (2020)

Vedolizumab Serum Trough Concentrations and Response to Dose Escalation in Inflammatory Bowel Disease
por: Vaughn, Byron P., et al.
Publicado: (2020)

Vedolizumab: Potential Mechanisms of Action for Reducing Pathological Inflammation in Inflammatory Bowel Diseases
por: Luzentales-Simpson, Matthew, et al.
Publicado: (2021)

Vedolizumab Immunogenicity With Long‐Term or Interrupted Treatment of Patients With Inflammatory Bowel Disease
por: Wyant, Timothy, et al.
Publicado: (2021)

Efficacy and safety of vedolizumab for pediatrics with inflammatory bowel disease: a systematic review
por: Fang, Shengbo, et al.
Publicado: (2022)

The Risk of Tuberculosis in Patients With Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab in Korea
por: Choi, Myeong Geun, et al.
Publicado: (2022)

The Effect of Vedolizumab on Spondyloarthritis Symptoms in a Cohort of Inflammatory Bowel Disease Patients
por: Huseynzada, Sinakhanım, et al.
Publicado: (2023)

Prevalence of Immunomodulator Use as Combination Therapy With Vedolizumab or Ustekinumab in Inflammatory Bowel Disease
por: Lutz, Megan, et al.
Publicado: (2023)

FNDC4 acts as an anti-inflammatory factor on macrophages and improves colitis in mice
por: Bosma, Madeleen, et al.
Publicado: (2016)

Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence
por: Scribano, Maria Lia
Publicado: (2018)

Effects of Anti-Integrin Treatment With Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases
por: Rath, Timo, et al.
Publicado: (2018)

Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease: current data and future directions
por: Ward, Mark G., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_n3fj94f7gi1nsdj5r4kkera8eg